RCT of Olanzapine for Control of CIV in Children Receiving HSCT Conditioning
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during
cancer treatment according to children and their parents. Most children receiving
hematopoietic stem cell transplant (HSCT) conditioning experience CINV despite receiving
antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a
track record of safe use in children with psychiatric illness, does not interact with
chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard
antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving
chemotherapy for HSCT conditioning.
Phase:
Phase 2
Details
Lead Sponsor:
The Hospital for Sick Children
Collaborators:
Children's Mercy Hospital Kansas City Columbia University Medical University of South Carolina St. Justine's Hospital University of California, San Francisco